Press release
Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC
DelveInsight's "Marginal Zone Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Marginal Zone Lymphoma, historical and forecasted epidemiology as well as the Marginal Zone Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Marginal Zone Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Marginal Zone Lymphoma Market Forecast [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=abnewsire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Marginal Zone Lymphoma Market Report:
*
The Marginal Zone Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In February 2025, Bristol Myers Squibb (NYSE: BMY) announced that its Phase 2 TRANSCEND FL trial assessing Breyanzi Registered (lisocabtagene maraleucel) in adults with relapsed or refractory indolent B-cell non-Hodgkin lymphoma achieved its primary endpoint in the marginal zone lymphoma (MZL) group. The findings revealed that Breyanzi produced a statistically significant and clinically meaningful overall response rate (ORR) in this patient population.
*
In January 2025, Verismo Therapeutics, a clinical-stage CAR T company specializing in KIR-CAR platform technology, announced the dosing of the first patient in its CELESTIAL-301 Phase 1 clinical trial. The infusion took place at the Sarah Cannon Research Institute (SCRI) at Colorado Blood Cancer Institute (CBCI) in Denver, Colorado. The CELESTIAL-301 trial is designed to evaluate the safety, tolerability, and preliminary efficacy of SynKIR Trademark -310 in patients with relapsed/refractory (r/r) B-cell Non-Hodgkin Lymphomas (B-cell NHL), including Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Marginal Zone Lymphoma (MZL). This Phase 1 multicenter trial is enrolling patients who have previously undergone CAR T therapy but relapsed or became refractory, as well as those who have never received CAR T therapy.
*
In August 2024, The UK National Institute for Health and Care Excellence (NICE) has endorsed BeiGene's Zanubrutinib (Brukinsa) for treating marginal zone lymphoma (MZL), a form of blood cancer, within the National Health Service (NHS). This approval introduces a new treatment option for patients in England, with the potential to slow cancer progression and reduce the need for additional chemotherapy.
*
In 2023, the United States recorded the highest number of marginal zone lymphoma (MZL) incidence cases among the 7MM, exceeding 8,000 cases. This number is projected to grow throughout the forecast period.
*
In gender-specific Marginal Zone Lymphoma incidence cases, males represent the predominant group.
*
In 2023, MALT lymphoma accounted for the largest proportion of incident cases in the US, comprising approximately 70%, followed by SMZL and NMZL.
*
In the US in 2023, stage-specific incidence of Marginal Zone Lymphoma was highest for Stage III-IV cases, followed by Stage I and Stage II.
*
YESCARTA and BREYANZI are gaining recognition as promising treatments for MZL, with BREYANZI anticipated to receive approval for third-line (3L+) MZL cases by 2026.
*
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
*
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
*
The Marginal Zone Lymphoma epidemiology based on gender analyzed that a higher number of males were affected by this disease, i.e., ~54%of the total incident MZL population in the United States, which is equivalent to ~4,300 cases. In comparison to this, for females, the number of cases observed was ~3,700 in 2022.
*
The Marginal Zone Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Marginal Zone Lymphoma pipeline products will significantly revolutionize the Marginal Zone Lymphoma market dynamics.
Marginal Zone Lymphoma Overview
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma, a cancer that originates in white blood cells called lymphocytes. MZL specifically affects a subset of these lymphocytes known as marginal zone B-cells, which are found at the edges, or margins, of lymphoid tissues like the lymph nodes, spleen, and mucosa-associated lymphoid tissue (MALT) such as the stomach, salivary glands, or other organs.
Get a Free sample for the Marginal Zone Lymphoma Market Forecast, Size & Share Analysis Report:
http://delveinsight.com/report-store/marginal-zone-lymphoma-market [http://delveinsight.com/report-store/marginal-zone-lymphoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Marginal Zone Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Marginal Zone Lymphoma Epidemiology Segmentation:
The Marginal Zone Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Marginal Zone Lymphoma
*
Prevalent Cases of Marginal Zone Lymphoma by severity
*
Gender-specific Prevalence of Marginal Zone Lymphoma
*
Diagnosed Cases of Episodic and Chronic Marginal Zone Lymphoma
Download the report to understand which factors are driving Marginal Zone Lymphoma epidemiology trends @ Marginal Zone Lymphoma Epidemiology Forecast [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=abnewsire&utm_medium=pressrelease&utm_campaign=gpr]
Marginal Zone Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Marginal Zone Lymphoma market or expected to get launched during the study period. The analysis covers Marginal Zone Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Marginal Zone Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Marginal Zone Lymphoma Therapies and Key Companies
*
REVLIMID (lenalidomide): Bristol-Myers Squibb
*
UKONIQ (umbralisib): TG Therapeutics
*
BREYANZI (lisocabtagene maraleucel): Bristol Myers Squibb
*
Yescarta: Gilead Sciences
*
Calquence: AstraZeneca
*
Betalutin: Nordic Nanovector
*
Obinutuzumab: Christian Buske
*
Rituximab: AbbVie
*
Ibrutinib: Pharmacyclics LLC
*
HMPL-689: Hutchison Medipharma
*
Zanubrutinib: Beigene
*
tafasitamab: Incyte Corporation
*
EO2463: Enterome
Discover more about therapies set to grab major Marginal Zone Lymphoma market share @ Marginal Zone Lymphoma Treatment Landscape [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=abnewsire&utm_medium=pressrelease&utm_campaign=gpr]
Scope of the Marginal Zone Lymphoma Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Marginal Zone Lymphoma Companies: Bristol-Myers Squibb, TG Therapeutics, Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC, Hutchison Medipharma, Beigene, Incyte Corporation, Enterome, and others
*
Key Marginal Zone Lymphoma Therapies: REVLIMID (lenalidomide), UKONIQ (umbralisib), BREYANZI (lisocabtagene maraleucel), Yescarta, Calquence, Betalutin, Obinutuzumab, Rituximab, Ibrutinib, HMPL-689, Zanubrutinib, tafasitamab, EO2463, and others
*
Marginal Zone Lymphoma Therapeutic Assessment: Marginal Zone Lymphoma current marketed and Marginal Zone Lymphoma emerging therapies
*
Marginal Zone Lymphoma Market Dynamics: Marginal Zone Lymphoma market drivers and Marginal Zone Lymphoma market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Marginal Zone Lymphoma Unmet Needs, KOL's views, Analyst's views, Marginal Zone Lymphoma Market Access and Reimbursement
To know more about Marginal Zone Lymphoma companies working in the treatment market, visit @ Marginal Zone Lymphoma Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/marginal-zone-lymphoma-market?utm_source=abnewsire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Marginal Zone Lymphoma Market Report Introduction
2. Executive Summary for Marginal Zone Lymphoma
3. SWOT analysis of Marginal Zone Lymphoma
4. Marginal Zone Lymphoma Patient Share (%) Overview at a Glance
5. Marginal Zone Lymphoma Market Overview at a Glance
6. Marginal Zone Lymphoma Disease Background and Overview
7. Marginal Zone Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Marginal Zone Lymphoma
9. Marginal Zone Lymphoma Current Treatment and Medical Practices
10. Marginal Zone Lymphoma Unmet Needs
11. Marginal Zone Lymphoma Emerging Therapies
12. Marginal Zone Lymphoma Market Outlook
13. Country-Wise Marginal Zone Lymphoma Market Analysis (2020-2034)
14. Marginal Zone Lymphoma Market Access and Reimbursement of Therapies
15. Marginal Zone Lymphoma Market Drivers
16. Marginal Zone Lymphoma Market Barriers
17. Marginal Zone Lymphoma Appendix
18. Marginal Zone Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=marginal-zone-lymphoma-market-growth-to-accelerate-in-forecast-period-20242034-delveinsight-analyzes-gilead-sciences-astrazeneca-nordic-nanovector-christian-buske-abbvie-pharmacyclics-llc]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Marginal Zone Lymphoma Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Gilead Sciences, AstraZeneca, Nordic Nanovector, Christian Buske, AbbVie, Pharmacyclics LLC here
News-ID: 4026324 • Views: …
More Releases from ABNewswire
Couples Therapy in Birmingham: Does It Really Work to Save Relationships?
Couples therapy in Birmingham helps partners improve communication, resolve conflict, and rebuild trust. Whether through relationship counselling or marriage counselling, Phinity Therapy offers a safe, supportive space for couples to reconnect. Therapy doesn't just address problems-it equips couples with lasting tools to strengthen love, intimacy, and resilience in their relationship.
Relationships are full of ups and downs. For many couples, the love that once came so naturally can sometimes feel distant.…
From Conflict to Collaboration: Phinity Therapy's Family Therapy in Birmingham S …
From Conflict to Collaboration: Phinity Therapy's Family Therapy in Birmingham supports families in overcoming challenges, improving communication, and finding healthier ways to connect.
Family relationships can be the most rewarding yet the most challenging connections in our lives. Families are built on love, shared experiences, and trust, but disagreements, misunderstandings, and life stresses can sometimes strain these bonds. When this happens, communication can break down and unresolved conflict may cause distance…
Droved Helps Local Businesses Win in the New Era of AI Search
Droved, aLocal SEO and AI Search Optimization agencybased in Toronto, helps service businesses across the United States and Canada, succeed in the age of AI-powered recommendations. With expertise inGoogle Maps SEO, Google Business Profile optimization, Generative Engine Optimization (GEO), and Local SEO for service businesses, Droved ensures clients stay visible across Google and AI platforms like ChatGPT, Gemini, Perplexity, and Claude.
Droved, a leading Local SEO agency specializing in AI search…
Lindy Summers Series Delivers a Trio of Essential Reads for New Moms, Stay Tuned …
Co-Authors Lindy Summers and Marc Seffelaar Release Groundbreaking Trio of Books, Including "The Fourth Trimester," Offering Real-World Advice for New Parents to Thrive, Not Just Survive
Parenting just got a little easier and a lot more supported. Authors Marc Seffelaar and Lindy Summers have teamed up to deliver a three-part parenting series that's already capturing the hearts of new moms and caregivers around the world.
With The Fourth Trimester: The Simplest Baby…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
